Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
pharmaphorum2y
GSK’s ZEJULA gets green light for NHS use
has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. Following a period of restricted access, the once-a-day capsule will ...
pharmaphorum1d
GSK hits another oncology hurdle as Zejula use is limited again
GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patients with ...
FiercePharma17d
GSK, with survey highlighting challenges facing gynecological cancer patients, kicks off initiative to close gaps in care
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, which is approved by the FDA in ovarian cancer, and Jemperli for ...
Hosted on MSN11mon
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study
GSK plc (NYSE: GSK) announced headline results ... (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, for primary advanced or recurrent ...